The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
| العنوان: | The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells |
|---|---|
| المؤلفون: | Lei Li, Yanwen Wang, Yanqi He, Li Zhang, Linhui Li, Dan Pu, Dan Liu, Yalun Li, Weimin Li |
| المصدر: | Biological Research, Vol 48, Iss 0, Pp 1-8 (2015) Biological Research, Volume: 48, Pages: 1-8, Published: 2015 Biological Research v.48 2015 SciELO Chile CONICYT Chile instacron:CONICYT Biological Research |
| بيانات النشر: | BMC, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Biology, Real-Time Polymerase Chain Reaction, Stem cell marker, Immune system, Adjuvants, Immunologic, Antigen, Toll like receptor 7, Antigens, CD, Osteogenesis, Transforming Growth Factor beta, Humans, Umbilical cord, lcsh:QH301-705.5, Cell Proliferation, Medicine(all), Imiquimod, L-Lactate Dehydrogenase, Agricultural and Biological Sciences(all), Interleukin-6, Tumor Necrosis Factor-alpha, Biochemistry, Genetics and Molecular Biology(all), Immunogenicity, Interleukin-8, Mesenchymal stem cell, Membrane Proteins, Cell Differentiation, TLR7, Flow Cytometry, Interleukin-12, Gene Expression Regulation, Toll-Like Receptor 7, lcsh:Biology (General), Immunology, Aminoquinolines, Leukocytes, Mononuclear, Mesenchymal stem cells, Stem cell, Pro-inflammatory molecules, CD80, Research Article |
| الوصف: | BACKGROUND: Mesenchymal stem cells (MSCs) are considered the best candidate in stem cells therapy due to their multipotent differentiation ability, low expression of co-stimulatory molecules (CD80, CD86, CD34 and HLA-II) and immunosuppression effects on in vivo immune responses. MSCs were now widely used in clinical trials but received no encourage results. The major problem was the fate of engrafted MSCs in vivo could not be defined. Some studies indicated that MSCs could induce immune response and result in the damage and rejection of MSCs. As toll like receptors (TLRs) are important in inducing of immune responses, in this study we study the role of TLR7 in mediating the immune status of MSCs isolated from umbilical cord. RESULTS: Our results indicated that TLR7 agonist Imiquimod could increase the proliferation of PBMC isolated from healthy human volunteers and release of lactate dehydrogenase (LDH) in supernatant from PBMC-UCMSCs co-culture system. Flow cytometry and quantitative PCR also confirmed the regulated expression of surface co-stimulatory molecules and pro-inflammatory genes (IL-6, IL-8, IL-12, TGF-β and TNF-α). And the down-regulation expression of stem cell markers also confirmed the loss of stemness of UCMSCs. We also found that the osteo-differentiation ability of UCMSCs was enhanced in the presence of Imiquimod. CONCLUSION: To our knowledge, this is the first report that activation of TLR7 pathway increases the immunogenicity of UCMSCs. Extensive researches have now been conducted to study whether the change of immune status will be help in tumor rejection based on the tumor-tropism of MSCs. |
| وصف الملف: | text/html |
| اللغة: | English |
| تدمد: | 0716-9760 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d6395a2f747878c80d37192d9942f63Test http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602015000100006&lng=en&tlng=enTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....4d6395a2f747878c80d37192d9942f63 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 07169760 |
|---|